Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells

BMC Cancer

Wei Xu²  Karen Ersland³  Jiacai Wu¹  Ashley M Brinkman² 

[1]Center for Science Research, Guilin Medical University, Guilin, Guangxi, China

[2]Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin – Madison, Madison, WI, USA

[3]University of Wisconsin Carbone Cancer Center Flow Cytometry Laboratory, University of Wisconsin – Madison, Madison, WI, USA

关键词: Knockdown cell lines;    Aryl hydrocarbon receptor;    Estrogen receptor;    Breast cancer;    Aminoflavone;   

Others  :  858814
DOI  :  10.1186/1471-2407-14-344

 received in 2013-12-11, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Background

Numerous studies have implicated the aryl hydrocarbon receptor (AhR) as a potential therapeutic target for several human diseases, including estrogen receptor alpha (ERα) positive breast cancer. Aminoflavone (AF), an activator of AhR signaling, is currently undergoing clinical evaluation for the treatment of solid tumors. Of particular interest is the potential treatment of triple negative breast cancers (TNBC), which are typically more aggressive and characterized by poorer outcomes. Here, we examined AF’s effects on two TNBC cell lines and the role of AhR signaling in AF sensitivity in these model cell lines.

Methods

AF sensitivity in MDA-MB-468 and Cal51 was examined using cell counting assays to determine growth inhibition (GI₅₀) values. Luciferase assays and qPCR of AhR target genes cytochrome P450 (CYP) 1A1 and 1B1 were used to confirm AF-mediated AhR signaling. The requirement of endogenous levels of AhR and AhR signaling for AF sensitivity was examined in MDA-MB-468 and Cal51 cells stably harboring inducible shRNA for AhR. The mechanism of AF-mediated growth inhibition was explored using flow cytometry for markers of DNA damage and apoptosis, cell cycle analysis, and β-galactosidase staining for senescence. Luciferase data was analyzed using Student’s T test. Three-parameter nonlinear regression was performed for cell counting assays.

Results

Here, we report that ERα-negative TNBC cell lines MDA-MB-468 and Cal51 are sensitive to AF. Further, we presented evidence suggesting that neither endogenous AhR expression levels nor downstream induction of AhR target genes CYP1A1 and CYP1B1 is required for AF-mediated growth inhibition in these cells. Between these two ERα negative cell lines, we showed that the mechanism of AF action differs slightly. Low dose AF mediated DNA damage, S-phase arrest and apoptosis in MDA-MB-468 cells, while it resulted in DNA damage, S-phase arrest and cellular senescence in Cal51 cells.

Conclusions

Overall, this work provides evidence against the simplified view of AF sensitivity, and suggests that AF could mediate growth inhibitory effects in ERα-positive and negative breast cancer cells, as well as cells with impaired AhR expression and signaling. While AF could have therapeutic effects on broader subtypes of breast cancer, the mechanism of cytotoxicity is complex, and likely, cell line- and tumor-specific.

【 授权许可】

   
2014 Brinkman et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012, 36:237-248.
• [2]Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
• [3]Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, Kasai M: Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 1996, 39:3461-3469.
• [4]Reiners JJ, Clift R, Mathieu P: Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor. Carcinogenesis 1999, 20:1561-1566.
• [5]Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989, 81:1088-1092.
• [6]Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD: An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275:343-349.
• [7]Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM: Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 2002, 62:143-153.
• [8]Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA: Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004, 3:715-725.
• [9]Stark K, Burger A, Wu J, Shelton P, Polin L, Li J: Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. PLoS One 2013, 8:e74525.
• [10]Cushman M, Nagarathnam D: Cytotoxicities of some flavonoid analogues. J Nat Prod 1991, 54:1656-1660.
• [11]Akama T, Ishida H, Shida Y, Kimura U, Gomi K, Saito H, Fuse E, Kobayashi S, Yoda N, Kasai M: Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem 1997, 40:1894-1900.
• [12]Akama T, Ishida H, Kimura U, Gomi K, Saito H: Structure-activity relationships of the 7-substituents of 5,4′-diamino-6,8,3′-trifluoroflavone, a potent antitumor agent. J Med Chem 1998, 41:2056-2067.
• [13]Ferriola PC, Cody V, Middleton E: Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 1989, 38:1617-1624.
• [14]Yamashita Y, Kawada S, Nakano H: Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 1990, 39:737-744.
• [15]Shi Q, Chen K, Morris-Natschke SL, Lee KH: Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 1998, 4:219-248.
• [16]Lu YF, Santostefano M, Cunningham BD, Threadgill MD, Safe S: Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem Pharmacol 1996, 51:1077-1087.
• [17]Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT: Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol 2004, 171:1688-1697.
• [18]Ciolino HP, Dankwah M, Yeh GC: Resistance of MCF-7 cells to dimethylbenz (a) anthracene-induced apoptosis is due to reduced CYP1A1 expression. Int J Oncol 2002, 21:385-391.
• [19]Callero MA, Loaiza-Pérez AI: The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. Int J Breast Cancer 2011, 2011:923250.
• [20]Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y: Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. Cancer Res 2006, 66:9656-9664.
• [21]Zheng Q, Sha X, Liu J, Heath E, Lorusso P, Li J: Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferase 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone. Mol Cancer Ther 2010, 9:2803-2813.
• [22]Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, Pommier Y: DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 2005, 65:5337-5343.
• [23]McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E: Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer 2008, 122:1665-1674.
• [24]Meng LH, Meng Z, Miao ZH, Veenstra TD, Pommier Y: Cytokeratin-RNA cross-linking mediated by the antitumor aminoflavone, 5-amino-2,3-fluorophenyl-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one. J Pharmacol Exp Ther 2008, 325:674-680.
• [25]Callero MA, Suárez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI: Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 2012, 41:125-134.
• [26]Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ: Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996, 140:173-179.
• [27]Denison MS, Nagy SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003, 43:309-334.
• [28]Probst MR, Reisz-Porszasz S, Agbunag RV, Ong MS, Hankinson O: Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. Mol Pharmacol 1993, 44:511-518.
• [29]Abel J, Haarmann-Stemmann T: An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem 2010, 391:1235-1248.
• [30]Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G: Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res 2010, 70:6837-6848.
• [31]Gioanni J, Le François D, Zanghellini E, Mazeau C, Ettore F, Lambert JC, Schneider M, Dutrillaux B: Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma. Br J Cancer 1990, 62:8-13.
• [32]Postlind H, Vu TP, Tukey RH, Quattrochi LC: Response of human CYP1-luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 1993, 118:255-262.
• [33]Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
• [34]Kalmes M, Neumeyer A, Rio P, Hanenberg H, Fritsche E, Blömeke B: Impact of the arylhydrocarbon receptor on eugenol- and isoeugenol-induced cell cycle arrest in human immortalized keratinocytes (HaCaT). Biol Chem 2006, 387:1201-1207.
• [35]Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E: beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS One 2010, 5:e9060.
• [36]Wiznerowicz M, Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003, 77:8957-8961.
• [37]Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992, 89:5547-5551.
• [38]Deuschle U, Meyer WK, Thiesen HJ: Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995, 15:1907-1914.
• [39]Stegeman JJ, Hahn ME, Weisbrod R, Woodin BR, Joy JS, Najibi S, Cohen RA: Induction of cytochrome P4501A1 by aryl hydrocarbon receptor agonists in porcine aorta endothelial cells in culture and cytochrome P4501A1 activity in intact cells. Mol Pharmacol 1995, 47:296-306.
• [40]Matsumura F: The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects. Biochem Pharmacol 2009, 77:608-626.
• [41]Blanchard JM: Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues. Biochem Pharmacol 2000, 60:1179-1184.
• [42]Reinicke KE, Kuffel MJ, Goetz MP, Ames MM: Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 2010, 66:575-583.
• [43]Dong B, Cheng W, Li W, Zheng J, Wu D, Matsumura F, Vogel CF: FRET analysis of protein tyrosine kinase c-Src activation mediated via aryl hydrocarbon receptor. Biochim Biophys Acta 1810, 2011:427-431.
• [44]Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
• [45]Hu X, Stern HM, Ge L, O’Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009, 7:511-522.
• [46]Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL: Differential anti-proliferative activities of poly (ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012, 134:649-659.
• [47]Seitz S, Wassmuth P, Plaschke J, Schackert HK, Karsten U, Santibanez-Koref MF, Schlag PM, Scherneck S: Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines. Genes Chromosomes Cancer 2003, 37:29-35.